(SAN) Sanofi - Ratings and Ratios
Vaccines, Oncology, Neurology, Immunology, Rare Diseases
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.30% |
| Yield on Cost 5y | 5.86% |
| Yield CAGR 5y | 5.34% |
| Payout Consistency | 99.7% |
| Payout Ratio | 74.8% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 21.5% |
| Value at Risk 5%th | 33.1% |
| Relative Tail Risk | -6.14% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.87 |
| Alpha | -21.47 |
| CAGR/Max DD | 0.01 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.364 |
| Beta | -0.076 |
| Beta Downside | 0.007 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.17% |
| Mean DD | 10.48% |
| Median DD | 10.36% |
Description: SAN Sanofi December 02, 2025
Sanofi (ticker SAN) is a global, diversified biopharma company that develops, manufactures, and markets therapeutics across immunology, rare diseases, neurology, oncology, and vaccines, including pediatric (polio, Hib), respiratory syncytial virus, hexavalent, influenza, meningitis, and travel-related vaccines.
The firm pursues an extensive partnership network: it has agreements with Exscientia (up to 15 oncology/immunology small-molecules), ABL Bio (alpha-synucleinopathy therapy ABL301), Innate Pharma (NK-cell engager), Blackstone Life Sciences (clinical development), IGM Biosciences (IgM antibodies), Kymera Therapeutics (IRAK4 degraders), Nurix Therapeutics (protein degradation), Denali Therapeutics (inflammatory diseases), Adagene (antibody discovery), Scribe Therapeutics (genome editing), and Provention Bio (teplizumab co-promotion), plus a strategic alliance with Abu Dhabi’s Department of Health for global vaccine development.
Key recent metrics: FY 2023 revenue of ≈ $44.9 billion, with vaccines contributing roughly 15 % of sales; R&D spend of ≈ $7.2 billion (≈ 16 % of revenue), supporting a pipeline of over 30 late-stage candidates. The sector is being driven by aging demographics, increasing demand for mRNA-based vaccines, and pricing pressures from biosimilars and generics.
For a deeper quantitative assessment, see the SAN analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 9.30b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 5.39 > 1.0 |
| NWC/Revenue: 4.22% < 20% (prev -42.56%; Δ 46.78% < -1%) |
| CFO/TA 0.13 > 3% & CFO 17.06b > Net Income 9.30b |
| Net Debt (12.85b) to EBITDA (12.23b): 1.05 < 3 |
| Current Ratio: 1.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.23b) vs 12m ago -1.52% < -2% |
| Gross Margin: 71.98% > 18% (prev 0.70%; Δ 7129 % > 0.5%) |
| Asset Turnover: 35.85% > 50% (prev 32.35%; Δ 3.50% > 0%) |
| Interest Coverage Ratio: 10.02 > 6 (EBITDA TTM 12.23b / Interest Expense TTM 945.0m) |
Altman Z'' (< 1.1 .. > 2.6) 4.94
| A: 0.01 (Total Current Assets 34.04b - Total Current Liabilities 32.10b) / Total Assets 129.79b |
| B: 0.53 (Retained Earnings 68.19b / Total Assets 129.79b) |
| C: 0.07 (EBIT TTM 9.47b / Avg Total Assets 128.13b) |
| D: 2.51 (Book Value of Equity 141.27b / Total Liabilities 56.26b) |
| Total Rating: 4.94= AAA |
ValueRay F-Score (Strict, 0-100) 75.29
| 1. Piotroski: 7.0pt |
| 2. FCF Yield: 15.54% |
| 3. FCF Margin: 37.47% |
| 4. Debt/Equity: 0.30 |
| 5. Debt/Ebitda: 1.05 |
| 6. ROIC - WACC: 3.48% |
| 7. RoE: 12.61% |
| 8. Revenue Trend: 11.60% |
| 9. EPS Trend: 7.42% |
What is the price of SAN shares?
Over the past week, the price has changed by -5.03%, over one month by -3.90%, over three months by -9.14% and over the past year by -17.34%.
Is SAN a buy, sell or hold?
What are the forecasts/targets for the SAN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 101 | 28.8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 75.8 | -3.4% |
SAN Fundamental Data Overview January 20, 2026
P/E Trailing = 15.416
P/E Forward = 9.6061
P/S = 2.1305
P/B = 1.3315
P/EG = 0.7168
Revenue TTM = 45.93b EUR
EBIT TTM = 9.47b EUR
EBITDA TTM = 12.23b EUR
Long Term Debt = 11.70b EUR (from longTermDebt, last quarter)
Short Term Debt = 8.49b EUR (from shortTermDebt, last quarter)
Debt = 21.75b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.85b EUR (from netDebt column, last quarter)
Enterprise Value = 110.71b EUR (97.86b + Debt 21.75b - CCE 8.91b)
Interest Coverage Ratio = 10.02 (Ebit TTM 9.47b / Interest Expense TTM 945.0m)
EV/FCF = 6.43x (Enterprise Value 110.71b / FCF TTM 17.21b)
FCF Yield = 15.54% (FCF TTM 17.21b / Enterprise Value 110.71b)
FCF Margin = 37.47% (FCF TTM 17.21b / Revenue TTM 45.93b)
Net Margin = 20.24% (Net Income TTM 9.30b / Revenue TTM 45.93b)
Gross Margin = 71.98% ((Revenue TTM 45.93b - Cost of Revenue TTM 12.87b) / Revenue TTM)
Gross Margin QoQ = 74.09% (prev 72.13%)
Tobins Q-Ratio = 0.85 (Enterprise Value 110.71b / Total Assets 129.79b)
Interest Expense / Debt = 1.04% (Interest Expense 227.0m / Debt 21.75b)
Taxrate = 19.38% (680.0m / 3.51b)
NOPAT = 7.63b (EBIT 9.47b * (1 - 19.38%))
Current Ratio = 1.06 (Total Current Assets 34.04b / Total Current Liabilities 32.10b)
Debt / Equity = 0.30 (Debt 21.75b / totalStockholderEquity, last quarter 73.26b)
Debt / EBITDA = 1.05 (Net Debt 12.85b / EBITDA 12.23b)
Debt / FCF = 0.75 (Net Debt 12.85b / FCF TTM 17.21b)
Total Stockholder Equity = 73.71b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.26% (Net Income 9.30b / Total Assets 129.79b)
RoE = 12.61% (Net Income TTM 9.30b / Total Stockholder Equity 73.71b)
RoCE = 11.09% (EBIT 9.47b / Capital Employed (Equity 73.71b + L.T.Debt 11.70b))
RoIC = 8.24% (NOPAT 7.63b / Invested Capital 92.60b)
WACC = 4.77% (E(97.86b)/V(119.61b) * Re(5.64%) + D(21.75b)/V(119.61b) * Rd(1.04%) * (1-Tc(0.19)))
Discount Rate = 5.64% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -0.79%
[DCF Debug] Terminal Value 88.43% ; FCFF base≈14.30b ; Y1≈17.64b ; Y5≈30.05b
Fair Price DCF = 713.9 (EV 875.04b - Net Debt 12.85b = Equity 862.19b / Shares 1.21b; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 7.42 | EPS CAGR: 22.01% | SUE: 1.43 | # QB: 1
Revenue Correlation: 11.60 | Revenue CAGR: 6.46% | SUE: 0.46 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.71 | Chg30d=-0.003 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=8.37 | Chg30d=-0.065 | Revisions Net=-3 | Growth EPS=+8.0% | Growth Revenue=+6.7%